Plant-Based Virus-like Particle (VLP) Vaccines Against Influenza and Hepatitis Viruses.
6 affiliations
- 1Department of Medical Nanotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan P.O. Box 45139-56184, Iran.
- 2Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada.
- 3Department of Biology, Payame Noor University, Tehran P.O. Box 19395-3697, Iran.
- 4Department of Biological Sciences and Biotechnology, School of Life Sciences, Botswana International University of Science and Technology, Private Bag 16, Palapye 1234, Botswana.
- 5College of Agricultural and Life Sciences, Cornell University, Roberts Hall, 215 Garden Avenue, Ithaca, NY 14850, USA.
- 6Independent Researcher, Burlington, ON L7T 0C8, Canada.
Abstract
The rapid evolution of pathogens, particularly viruses, poses a continuous threat to global public health, necessitating the development of highly scalable and cost-effective vaccine platforms. Plant-based virus-like particles (VLPs) have emerged as a transformative approach in vaccinology, leveraging the innate capacity of plant systems to produce highly immunogenic, non-infectious, and structurally authentic viral mimics. VLP-based recombinant antigens contained within the plant tissues (particularly in seeds) show better stability and can be transported and stored at ambient temperatures, without the requirement of a cold chain framework, and edible vaccines offer needle-free vaccine administration. Plant-based expression systems use natural cellular structures such as plant cell walls and seed endosperms to encase antigens, functioning as a natural shield against digestion and thermal degradation. Grain host plants are inimitably adapted for prolonged storage owing to natural seed desiccation wherein recombinant antigens accumulate within vacuoles or intracellular protein bodies segregated from active degradation. By simply cultivating more plants, vaccine production can be scaled up while transient plant expression systems speed up production within a few weeks, which is critical for quick responses to emerging new disease outbreaks. By genetic modification, plants can be used to express several antigens, facilitating the development of multi-component vaccines against many diseases at a single shot. Recently, plant-derived VLP vaccines, principally targeting influenza and hepatitis viruses, have been shown to elicit robust immune responses through the expression of their surface antigens in plants such as lettuce, potato, and tobacco (Nicotiana benthamiana). Despite their potential, significant challenges persist, including the achievement of consistent dosing, the attainment of high and reproducible expression levels, and the navigation of complex regulatory frameworks for plant-derived pharmaceuticals which remain unsolved. The current review focuses on recent developments in the production of plant-based influenza and hepatitis vaccines and explores the advantages, challenges, and application of such vaccines in combating these infections.
Related
- Self-amplifying RNA vaccines encoding chimeric and mosaic hemagglutinins confer immunity against phylogenetically diverse influenza A viruses
- Computationally Optimized H1 and H3 Hemagglutinin Messenger RNA Vaccines Confer Broad Protective Immunity Against Modern Influenza Viruses
- N1 neuraminidase monoclonal antibodies 2H08 and 3H03 have decreased binding and inhibition properties against H1N1 influenza viruses circulating after 2018
- Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies
- Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts
BibTeX
@article{shahgolzari2026plantbased,
title = {{Plant-Based Virus-like Particle (VLP) Vaccines Against Influenza and Hepatitis Viruses.}},
author = {Mehdi Shahgolzari and Kathleen Hefferon and Afagh Yavari and Goabaone Gaobotse and Kabo Masisi and Mehrin Faija and Abdullah Makhzoum and Srividhya Venkataraman},
journal = {Vaccines},
year = {2026},
month = oct,
doi = {10.3390/vaccines14100912},
url = {https://europepmc.org/article/MED/42931441},
note = {CC BY},
}
RIS
TY - JOUR
TI - Plant-Based Virus-like Particle (VLP) Vaccines Against Influenza and Hepatitis Viruses.
AU - Mehdi Shahgolzari
AU - Kathleen Hefferon
AU - Afagh Yavari
AU - Goabaone Gaobotse
AU - Kabo Masisi
AU - Mehrin Faija
AU - Abdullah Makhzoum
AU - Srividhya Venkataraman
PY - 2026
DA - 2026/10/20
JO - Vaccines
DO - 10.3390/vaccines14100912
UR - https://europepmc.org/article/MED/42931441
AB - The rapid evolution of pathogens, particularly viruses, poses a continuous threat to global public health, necessitating the development of highly scalable and cost-effective vaccine platforms. Plant-based virus-like particles (VLPs) have emerged as a transformative approach in vaccinology, leveraging the innate capacity of plant systems to produce highly immunogenic, non-infectious, and structurally authentic viral mimics. VLP-based recombinant antigens contained within the plant tissues (particularly in seeds) show better stability and can be transported and stored at ambient temperatures, without the requirement of a cold chain framework, and edible vaccines offer needle-free vaccine administration. Plant-based expression systems use natural cellular structures such as plant cell walls and seed endosperms to encase antigens, functioning as a natural shield against digestion and thermal degradation. Grain host plants are inimitably adapted for prolonged storage owing to natural seed desiccation wherein recombinant antigens accumulate within vacuoles or intracellular protein bodies segregated from active degradation. By simply cultivating more plants, vaccine production can be scaled up while transient plant expression systems speed up production within a few weeks, which is critical for quick responses to emerging new disease outbreaks. By genetic modification, plants can be used to express several antigens, facilitating the development of multi-component vaccines against many diseases at a single shot. Recently, plant-derived VLP vaccines, principally targeting influenza and hepatitis viruses, have been shown to elicit robust immune responses through the expression of their surface antigens in plants such as lettuce, potato, and tobacco (Nicotiana benthamiana). Despite their potential, significant challenges persist, including the achievement of consistent dosing, the attainment of high and reproducible expression levels, and the navigation of complex regulatory frameworks for plant-derived pharmaceuticals which remain unsolved. The current review focuses on recent developments in the production of plant-based influenza and hepatitis vaccines and explores the advantages, challenges, and application of such vaccines in combating these infections.
SN - 2076-393X
ER -